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1. INTRODUCTION
The efficacy of combining adriamycin and dexamethasone with 
the proteosome inhibitor bortezomib (original investigative name 
PS341) as induction therapy prior to autologous stem cell trans-
plantation (ASCT) for previously untreated patients with mul-
tiple myeloma was clearly shown in two phase 2 studies [1,2]. 
Their observations were subsequently confirmed in a large multi- 
national randomized phase 3 clinical study [3].
Since the introduction of thalidomide and bortezomib to clinical 
practice at the start of this century the range of therapeutic options 
for patients with myeloma is growing exponentially, with no fewer 
than seven new drug approvals by the FDA since 2015 (Ixazomib [4], 
Daratumumab [5], Elotuzumab [6], Panobinostat [7], Isatuximab 
[8], Selinexor [9], and Belantamab [10]) with many more candi-
date therapeutic agents in the pipeline. All of these drugs are and 
will be expensive, on account of not only development cost but 
also the significant cost of undertaking large randomised clinical 
trials to demonstrate improved efficacy. Furthermore, the range of 
options for combination therapy will, of necessity, increase, giving 
rise to the problem of how to select most beneficial options for fur-
ther investigation [11]. In addition, more new agents are currently 
under investigation, with a number of them showing sufficient 
promise as likely to achieve approval [12]. Recently, these trials have 
relied on comparisons of progression free survival (PFS) (often 
after two or more previous regimens) as their end point, in view of 
the difficulties in using overall survival, which can be significantly 
affected by downstream regimens. On occasion, such results have 
been used to grant accelerated regulatory approval [13]. As a result 
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A B S T R AC T
When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated 
patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD 
in relapsed or refractory patients by comparing the response rate obtained in 53 patients who received vincristine, 
adriamycin and dexamethasone (VAD) or equivalent regimen as induction therapy, using a comparative design in which each 
patient acted as their own control. Whereas 25 patients had a positive response to VAD, 37 patients had a response to PAD ≤ 
partial remission (PR) (p = 0.023). Using the more stringent response level of very good PR (VGPR) the results favored the 
PAD regimen very significantly (p = 0.006) (McNemars test). Similar results were seen using paired M-protein levels from 
individual patient comparisons. As the PAD regimen was subsequently adopted as the re-induction therapy in the British Society 
for Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) trial, now concluded, we have 
retrospectively analyzed the findings from both studies. Comparison of response rates and adverse effects of patients having 
had previous autologous transplantation (Cohort 1) with the corresponding data from Myeloma X showed close correlation. 
These findings provide evidence that rapid results may be obtained in the evaluation of newly introduced, and potentially highly 
effective, anti-tumour agents by direct comparison to the response to the immediately preceding standard regimen, particularly 
in relatively resistant tumours.
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of a recent  publication from the International Myeloma Working 
Group (IMWG), PFS after treatment of a first relapse (PFS2) has 
become a recognised endpoint for evaluation of newer agents in 
their initial assessment [14].
Most patients with myeloma present well-defined and easily mea-
sured markers of disease activity (response and progression) in 
the form of a serum paraprotein or specific serum free light chain. 
Depth of response (DoR) is also well-categorised, and is also related 
to response duration [6], which is recognized to shorten with each 
successive relapse [15]. In this study, we show that advantage can 
be taken of these facts to develop analyses requiring relatively small 
numbers of patients who act as their own controls, thus reducing 
the size of the required cohort and, potentially, the costs. As the best 
outcomes in myeloma are usually obtained at induction [15], the 
achievement of response equivalent to or better than that obtained 
with initial therapy at diagnosis (VAD in this study; vincristine, 
adriamycin and dexamethasone) by the therapy being tested (in 
this instance PAD; bortezomib, adriamycin and dexamethasone) at 
relapse after VAD would be indicative of its superior effectiveness. 
Similarly, if a therapeutic PAD-based response could be obtained in 
patients initially refractory to VAD this would also indicate superior 
clinical effectiveness. Furthermore, using DoR and PFS2 as markers 
of therapeutic efficacy, very rapid signals of treatment effectiveness 
can be generated. In this report, we show the results of our phase 2 
study showing the same effects seen with PAD therapy in subsequent 
larger studies in identical clinical circumstances. Obtaining positive 
signals in this way facilitates the selection of the most promising 
regimens with which to proceed to phase 3 trials, and gives a good 
estimate of the likely common side effects. With the advent of new 
tumor markers and highly accurate cross-sectional imaging for solid 
tumors, it is possible that this approach might be applied to other 
malignancies, facilitating the optimal design of future pivotal trials.
2. MATERIALS AND METHODS
Patients with relapsed myeloma requiring further treatment were 
eligible if they had previously received induction therapy with 
VAD or VAD like regimen [cyclophosphamide, vincristine, adri-
amycin and dexamethasone (C-VAD), cyclophosphamide, vin-
cristine, adriamycin, melphalan and prednisolone (C-VAMP), 
idarubicin and dexamethasone (Z-DEX)] [16]. Patients previ-
ously given induction therapy with VAD (or VAD like regimen) 
were subsequently treated with PAD in three separate cohort: (1) 
Patients who had proceeded to ASCT and subsequently relapsed; 
(2) Patients not transplanted but now requiring further ther-
apy and; (3) Patients refractory to VAD (given as initial therapy) 
and requiring further treatment. PAD therapy was administered as 
described by Oakervee et al. [1]. Patients in Cohorts 1 and 2 were 
permitted to have one additional line of therapy (but not a second 
transplant) prior to trial entry. Patients in Cohort 3 on being found 
refractory to VAD or a VAD like regimen proceeded to PAD with-
out any intervening therapy. For the purposes of analyzing their 
response to PAD, their paraprotein level on starting PAD was used 
as baseline for assessing response to this regimen.
As patients had already received therapy containing an anthra-
cycline and dexamethasone prior to being given PAD, detailed 
comparisons of responses (and the potential benefit of borte-
zomib) could be made using the data obtained from previous 
treatment compared to that with PAD therapy. In the primary anal-
ysis, responses were assessed by the European Blood and Marrow 
Transplant (EBMT) group criteria in use at that time [17] with the 
addition of very good partial remission (VGPR) (indicating a 90% 
paraprotein response), and a comparison of PAD and VAD made. 
The second end point compared best M-protein responses obtained 
with VAD and PAD therapy in individual patients. The % fall of the 
M-protein on VAD therapy was compared to the % fall in M-protein 
achieved by PAD treatment. Safety and toxicity data for each 
treatment cycle were collected using the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 3.0 during 
routine clinical assessments at each centre (All patients were included 
in the analyses except one in group 1 who was oligosecretory; com-
parisons were made using remission status from bone marrow sam-
ples and this patient was not included in this comparison.).
Eligible patients had Eastern Cooperative Oncology Group 
(ECOG) status of 0–2, platelets <25 ´ 109/L, haemoglobin >80 g/L, 
and neutrophils >1.0 ́  109/L with creatinine clearance >30 mL/min. 
In addition, patients were excluded if the ejection fraction (EF) 
[measured by echocardiography or multigated acquisition scan 
(MUGA)] was less than 40%, and therapy was to be stopped if 
the EF fell by more than 10% after any two cycles of therapy. 
Neuropathy of greater than grade 2 was also an exclusion criterion 
for treatment discontinuation. The study received appropriate eth-
ical review at participating institutions and was conducted accord-
ing to the Declaration of Helsinki, the International Conference on 
Harmonisation Guidelines for Good Clinical Practice. All patients 
provided written informed consent. The trial was registered with 
the Irish Clinical Oncology Research Group number ICORG 05-01. 
Cohort 1 was used as the pilot study for the induction therapy 
given in the British Society for Blood and Marrow Transplantation/
United Kingdom Myeloma Forum (BSBMT/UKMF) Myeloma X 
Relapse (Intensive) Trial, which investigated the efficacy of a fur-
ther ASCT in patients relapsing after a >18 month treatment-free 
interval following a first ASCT [18]. The comparator group received 
oral cyclophosphamide weekly (400 mg/m2) for 12 weeks. The data 
obtained from this non-intensive arm have subsequently been used 
in this study for comparison with Cohort 1. Comparison was made 
of demographic matching, response rates and adverse effects.
2.1. Statistical Methods
The primary outcome was to determine the response status (partial 
response, PR, or complete response, CR) to PAD therapy. Assuming 
that 25% of patients reaching CR or PR state would be unsatisfactory 
(null hypothesis) and that 50% of patients reaching this state would 
be satisfactory (alternative hypothesis) a single stage phase 2 design 
with 23 patients per group was required. All analyses were  performed 
on an intention to treat basis. All statistical tests were at the two-
sided p-value of 0.05. Patients were compared for their difference 
in response to previous VAD and to PAD therapy using McNemar’s 
test. Confidence intervals were produced using Wilson’s method. For 
the secondary analysis, difference in the M-protein level during the 
previous VAD and the PAD therapy was tested for significance using 
the paired t-test or with a non-parametric option if the variables were 
non-normal. PFS and overall survival (OS) were estimated using the 
Kaplan–Meier method [19]. In all time-to-event analyses, patients 
who had not  experienced the event in question (progression or death) 
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were censored on the last date seen. As only one patient in Cohort 
1 had a second ASCT, this cohort was used for comparison with the 
non-intensive arm of the Myeloma X study, although it should be 
noted that the Myeloma X patients did receive “intensive” oral cyclo-
phosphamide for up to 12 weeks.
3. RESULTS
The study opened in February 2006 and Cohort 1 was fully recruited 
by the end of February 2007. Cohort 3 was fully recruited by June 
2009 and the study was closed with a total of seven patients recruited 
to Cohort 2. The characteristics of all 53 patients (by cohort) 
are shown in Table 1. Cytogenetic studies were not performed. 
Eight patients had received thalidomide-based therapy for their 
first relapse in Cohort 1. Following PAD therapy, 17 patients pro-
ceeded to transplant: one (second) transplant in Cohort 1, two 
in Cohort 2 and 14 in Cohort 3, including one matched and one 
mismatched allogenic transplant.
3.1. Response Data
3.1.1. EBMT response (modified) findings
The best response to the PAD chemotherapy in each cohort 
are shown in Table 2. Thirty seven of the 53 patients achieved 
a response of ≥PR (70%), therefore not only exceeding the level 
required (25%) to avoid a negative result, but also reaching the 
target indicating a satisfactory result (50%). Table 3a shows there 
are 18 discordant pairs in favor of PAD treatment, compared to 
only six discordant pairs in favor of VAD, suggesting a positive 
effect in favor of the PAD chemotherapy (Exact McNemar test; 
p = 0.023). When the more stringent response level of ≥VGPR 
(>90% reduction of paraprotein) was used in a similar com-
parison (Table 3a), the analysis showed an even stronger result 
in favour of the PAD combination (p = 0.006). When Cohorts 
1 and 3 were analysed using a cut off of ≤PR versus PR or greater 
and also ≤VGPR versus VGPR or greater, the McNemar’s exact 
probability test gave results of p = 0.727, p = 0.070, p < 0.001 and 
p = 0.250 respectively (Table 3b and 3c).
Table 1 | Baseline characteristics of patients with relapsed (Cohorts  
1 and 2) or refractory (Cohort 3) myeloma
Cohort 1 2 3
Number 23 7 23
Gender
Male/Female 14/9 5/2 17/6
Age
 Median 58 59 57
 Range 41–70 50–72 35–70
Type of myeloma
IgG 12 2 15
IgA 6 5 6
BJM 4 – 1
NS 1 – –
Relapse status
First 15 7 Refractory
Second 8 0 –
Previous chemo
VAD 13 5 15
VAMP 1 0 0
C-VAMP 6 2 0
C-VAD 0 0 2
Z-DEX 3 0 6
Cycles of previous  
chemotherapy
Median 5 4 4
Range 4–6 3–6 2–6
Time from diagnosis  
to registration
49 11 6
Months 20–179 4–83 2–34
ISS at trial entry
1 10 2 13
2 5 2 5
3 4 3 3
Unknown 4 0 2
ECOG at trial entry
0 8 0 9
1 15 4 9
2 3 2 4
3 1 1 –
Cycles of PAD therapy
Median 4 4 4
Range 2–6 3–4 2–6
BJM, Bence Jones myeloma; NS, Non Secretory myeloma.
Table 2 | Best overall response to PAD
CR PR MR NC PD
Cohort 1 8 (35%) 10 (43%) 3 (13%) – 2 (9%)
Cohort 2 1 (14%) 4 (57%) 1 (14%) – 1 (14%)
Cohort 3 2 (9%) 12 (52%) 6 (26%) 2 (9%) 1 (4%)
MR, minimal response; NC, no change; PD, progressive disease.
Table 3a | Overall comparison of response to VAD  
and PAD: exact McNemar test
Response to PAD
Response to VAD <PR PR or greater Total p-values
<PR 10 18 28 0.023
PR or greater 6 19 25
Total 16 37 53
<VGPR 36 11 47 0.006
<VGPR or greater 1 5 6
Total 37 16 53
Table 3b | Comparison of response to VAD and PAD 
Cohort 1: exact McNemar test
Response to PAD
Response to VAD <PR PR or greater Total p-values
<PR 0 3 3 0.727
PR or greater 5 15 20
Total 5 18 23
<VGPR 12 7 19 0.0703
<VGPR or greater 1 3 4
Total 13 10 23
30 T.C.M. Morris et al. / Clinical Hematology International 3(1) 27–33
and three patients experiencing this at least once in Cohorts 
1–3, respectively, while Grade 3 and 4 neutropenia was noted 
in seven, three and seven patients. While Grade 1/2 peripheral 
(sensory) neuropathy was observed in up to 40% of patients, the 
number experiencing Grade 3 and 4 was limited (Cohort 1 n = 3, 
Cohort 2 n = 1 and Cohort 3 n = 3). Fatigue was also commonly 
noted, but the incidence of Grade 3/4 was much lower with one, 
one and two in each of the three cohorts. One patient developed 
fatal pseudomembraneous colitis with neutropenia, pseudomo-
nal sepsis and died.
3.1.5.  Comparison of cohort 1 and the 
non-intensive arm of Myeloma X
Comparison of characteristics and side effect profile of patients 
in Cohort 1 and the non-intensive arm of Myeloma X are shown in 
Table 4, where it can be seen that patients are well matched (taking 
into account that eight patients in Cohort 1 received thalidomide 
as a second therapy prior to trial entry). There is a striking con-
cordance between the response rate (≥PR and ≥VGPR) and PFS of 
the two studies. The difference in OS may be related to the fact 
that, for patients relapsing in Cohort 1, lenalidomide would not 
Figure 1 | “Waterfall plot” for percentage of change in paraprotein levels 
following VAD and PAD chemotherapy (Two patients in Cohort 3 
progressed on VAD).
Figure 2 | Kaplan–Meier plots of overall survival (a, upper plot) and 




Table 3c | Comparison of response to VAD and PAD 
Cohort 3: exact McNemar test 
Response to PAD
Response to VAD <PR PR or greater Total p-values
<PR 9 14 23 <0.001
PR or greater 0 0 0
Total 9 14 23
<VGPR 20 3 23 0.250
<VGPR or greater 0 0 0
Total 20 3 23
3.1.2. M-protein levels
The percentage change in M-protein levels achieved by VAD 
and VAD-like therapy was compared to the percentage decrease 
in M-protein levels achieved by PAD therapy. Figure 1 illustrates 
the results for all patients. In Cohort 1 the percentage median 
decrease (±SD) in paraprotein for VAD was 63% (±25) % and for 
PAD 79% (±29) % (p = 0.233), clearly not an inferior result. In 
Cohort 3 the median decrease in M-protein with VAD was 19% 
(±44) % and when these patients received PAD it was 60% (±26) % 
(p = 0.0002).
3.1.3.  Progression free survival and  
overall survival
Figure 2a and 2b shows Kaplan–Meier plots of the PFS and OS 
for Cohorts 1–3. The PFS was 10, 4 and 25 months, respectively, 
 following PAD therapy (with no additional therapy given except for 
those patients proceeding to transplantation (n = 1, 2 and 14 respec-
tively). The median OS was 35, 63 and 76 months, respectively. 
3.1.4. Adverse effects
Severe (Grade 3 and 4) cytopenias were the principal side effects 
noted, with Grade 3 and 4 thrombocytopenia in eight, four 
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Age (years) 60 61
Median time from diagnosis  
to first relapse (months)
47 39
Range (months) 20–179 18–150
PR or better post PAD (%) 79 78
PFS (months) 10 11
OS (months) 35 52
Serious adverse events (%) 47 45
Anaemia (%) 3 7
Neutropenia (%) 22 42
Thrombocytopenia (%) 39 52
Infection (%) 4 9
Nausea (%) 13 7
Vomiting (%) 4 3
Diarrhoea (%) 0 5
Sensory neuropathy (%) 4 10
have been available, except in a limited number of clinical trials, 
whereas lenalidomide (or pomalidomide) was widely available to 
patients relapsing in Myeloma X [20]. The side effect profile was 
also similar (Table 4).
4. DISCUSSION
Poor uptake of clinical trials by cancer treating institutions, sub- 
optimal enrolment and failure to complete recruitment are all 
 barriers to advancing treatment of cancer patients [21]. A simple 
trial design requiring relatively small numbers of patients and capa-
ble of being carried out on multiple sites offers a potential solution 
to the recruitment of sufficient numbers of participants (patients), 
and the speed with which the study can be concluded, allowing 
recruitment to large phase 3 trials to be concentrated on studies 
which have the potential to change clinical practice for the better. 
This study acted as a feasibility study for the Cancer Research UK 
Myeloma X, which was for patients in first relapse [18,22], and 
assessed two therapeutic approaches by comparing PFS following 
the start of second line therapy (PFS2). Results from this major 
study were incorporated into the IMWG recommendations for the 
management of relapsed multiple myeloma [23].
Response and depth of response are convenient and widely used 
markers of therapeutic efficacy in myeloma. In this study, we show 
that a very demanding target in terms of achieving a depth of 
response at least as good as that achieved by the patients’ induction 
therapy on first line treatment has been clearly achieved by the sub-
stitution of the trial medication (in this instance, bortezomib for vin-
cristine) in the now outdated VAD regimen for patients in Cohort 1. 
This also appears true for the small number of patients in Cohort 2 
and, particularly, for Cohort 3, in which all patients initially failed to 
achieve at least PR. Note that the responses to PAD were calculated 
using the paraprotein level observed at the time of commencing PAD 
therapy and not that at diagnosis, again raising the bar very high.
Comparison of the characteristics of Cohort 1 in the present study 
and patients entered into Myeloma X shows that, while the mean 
age of the PAD Cohort 1 is 3 years lower than Myeloma X and con-
tains a slightly higher proportion of women, there is broad similar-
ity between the isotypes, International Staging System (ISS) stage 
and time to progression after first ASCT of the two groups. After 
PAD induction for all patients in Myeloma X followed by periph-
eral blood stem cell harvesting (if necessary) to support a second 
ASCT, patients were randomized to a second dose melphalan at 
200 mg/m2, ASCT or to 12 weeks intensive (400 mg/m2) cyclophos-
phamide therapy. This latter group experienced a PFS of 11 months, 
a figure very similar to the control arm in other randomised con-
trolled clinical trials of patients in first relapse [7,24]. As can be 
seen (Table 2) in this study, when patients received up to six cycles 
of PAD therapy (median 4) versus four (median 3) cycles of the 
same therapy plus consolidation (now seen as relatively ineffective, 
but commonly used at the time of the Myeloma X study design), 
the duration of PFS in the PAD study was an accurate forecast of 
PFS in the Myeloma X trial. Importantly, the safety signals noticed 
in our study also correlated well with Myeloma X (excluding those 
clearly related to the experimental ASCT) arm. The difference in 
OS may reflect the use of salvage ASCT as third line therapy in 
Myeloma X along with the greater availability of lenalidomide and 
other agents in the later timeframe of Myeloma X [20].
We have thus demonstrated a simple trial design in which a highly 
efficacious drug is substituted for a less effective agent in an estab-
lished regimen. However, the results from Cohort 3 suggest that 
use of a modified (or indeed a totally new regimen) directly after 
demonstration of (relative) failure of the first regimen may be capa-
ble of sending an even stronger signal of the new regimen’s efficacy. 
Failure to respond to first line therapy (even VAD) is a clear sign 
of resistant disease in myeloma, and is associated with a poorer 
prognosis. Immediately switching to a more effective regimen is 
appropriate, allowing most of the transplant-eligible patients in 
Cohort 3 to proceed to ASCT. While the superiority of bortezomib 
over vincristine is hardly a surprise, we suggest this style of trial 
design is capable of producing clear signs of efficacy with small 
numbers of patients and correspondingly reduced costs in a short 
timeframe. Cohort 1 was filled within 12 months of opening in a 
small number of centres and was first reported 30 months later at 
the Haematology Association of Ireland Annual meeting and a few 
months later at the IMWG meeting of 2009 [25]. Larger clinical 
trial groups would clearly be capable of improving on this recruit-
ment period. Although response rates, PFS2 and depth of response 
have all been used in obtaining regulatory approval, the aim of this 
manuscript was to look at designing sequential trials more effi-
ciently rather than using this method for regulatory approval per se. 
We seek to streamline the process to randomized clinical trials by 
identifying the most promising drugs in rigorous phase 2 trials. 
Therefore, we suggest that new promising agents may be usefully 
studied in comparison with previous therapy to  economically and 
promptly assess efficacy and facilitate timely and meaningful phase 
3 trial development and clinical use.
5. CONCLUSION
Substituting bortezomib for vincristine in the VAD regimen (PAD) 
proved therapeutically effective in patients with myeloma already 
treated with VAD, using a simple trial design with small numbers 
of patients. The data obtained from this small study appeared to 
accurately predict the response rates and common side effect pro-
file in the larger BSBMT/UKMF Myeloma X study. This approach 
appears capable of giving an accelerated estimate of the efficacy 
of a novel regimen, and could be of benefit in selecting the most 
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promising new anti-cancer chemotherapeutic agents for large (and 
expensive) phase 3 clinical trials.
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